If you need help accessing our website, call 855-698-9991
Affiliated Provider
Affiliated providers provide medical care at an NYU Langone location or a private practice, and are not employed by NYU Langone Health.

Daniel E. Roberts, MD

Affiliated Provider
Affiliated providers provide medical care at an NYU Langone location or a private practice, and are not employed by NYU Langone Health.
  • Specialty: Psychiatry
  • Treats: Adults
  • Language: English
View Locations

Growing up in a working-class family with parents struggling with significant medical conditions and a brother with an intellectual disability, I saw firsthand the struggles of everyday life and the challenges people face living with illness and limited resources. The mental health challenges of both my immediate and extended family members and my own lived experiences inspired my long-standing interest in the inner workings of the mind and brain. This led me to pursue clinical social work and ultimately psychiatry—a path that I felt would allow me to use my passion for knowledge, empathy, and life experiences to help others.

 I am a clinical assistant professor of psychiatry at NYU Grossman School of Medicine, and I am also the attending psychiatrist at the NYU Langone World Trade Center Health Program, where I provide trauma-informed care to patients affected by the 9/11 terrorist attacks. In addition to this role, I am also a clinician-researcher at the NYU Langone Center for Psychedelic Medicine, where I work on clinical trials exploring novel psychedelic therapies for a variety of conditions such as depressive disorders, posttraumatic stress disorder, substance use disorders, and cancer-related distress, and I am highly active in the training and supervision of therapists learning psychedelic therapy.

 My approach to patient care is rooted in a desire to truly understand each person’s unique history and suffering, combining research-based knowledge with a strong background in psychotherapy to offer tailored treatment for every individual.

Board Certifications
  • American Board of Psychiatry & Neurology - Psychiatry, 2022
Education and Training
  • Residency, NYU Grossman School of Medicine, Psychiatry, 2022
  • Fellowship, Psychoanalytic Association of New York (PANY), Psychoanalytic, 2021
  • MD from Michigan State University, 2018

Is this your profile?

Edit profile

Please call the office for information about accepted insurance plans.

Daniel E. Roberts, MD does not accept insurance.

Locations and Appointments

WTC Health Program Clinical Center of Excellence

38 East 32nd Street, 4th Floor, New York, NY 10016

Center for Psychedelic Medicine

1 Park Avenue, 8th Floor, New York, NY 10016

Research Summary

My primary research focus is on psychedelic medicine and psychedelic-assisted therapy for a range of mental health conditions. I wanted to pursue my psychiatry residency training at NYU because of its leadership in modern psychedelic research, and as part of the Research Career Development Track, I had dedicated time to engage in psychedelic research and scholarship. Since 2019, I have been actively involved in clinical trials exploring the therapeutic potential of psychedelics, including Phase 2 and 3 psilocybin studies for depression, the Phase 3 MDMA study for PTSD, and trials investigating psilocybin for alcohol, opioid, and nicotine use disorders. Additionally, I have contributed to trials examining psilocybin for cancer-related depression, anxiety, and existential distress, as well as a novel psychedelic analogue for postpartum depression. Beyond psychedelic research, my work spans various areas of psychiatry, including substance use disorders, personality disorders, academic medical education, and child and adolescent mental health.

  • A Phase 2b Randomized Double-blind Placebo-controlled Multi-center Study of the Effects of Psilocybin-assisted Psychotherapy on Psychiatric and Existential Distress in Advanced Cancer

    Learn More
  • 5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder

    Learn More
  • A Phase 3 Randomized Double-Blind Multicenter Study to Evaluate the Efficacy Safety and Tolerability of Psilocybin in Adults with Major Depressive Disorder

    Learn More
View All Research Studies (4)

Read All Publications (17)